Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Fudan-Zhangjiang released its 2026 interim report, with net profit attributable to the parent company at 36.895 million yuan, up 545.57% from the same period last year. Total operating revenue was 372 million yuan, down 4.58% year on year. Net cash inflow from operating activities was 82.6267 million yuan, up 32.81% year on year, marking three consecutive years of growth. The company's latest asset-liability ratio was 10.79%, gross margin was 91.63%, return on equity was 1.71%, and diluted earnings per share was 0.04 yuan.

Fudan-Zhangjiang released its semi-annual report for 2026, showing net profit attributable to shareholders of the listed company of 36.895 million yuan, a year-on-year increase of 545.57%. The company achieved operating revenue of 372 million yuan, down 4.58% year on year. The profit growth was mainly due to research and development expenses falling by approximately 44 million yuan compared with the same period last year.

On the evening of August 14, several A-share listed companies disclosed their half-year reports, with first-half net profit more than doubling year on year. Only Education achieved net profit attributable to the parent of 31.12 million yuan, up 977.30 percent year on year; Fudan-Zhangjiang posted net profit attributable to the parent of 36.90 million yuan, up 545.57 percent; Cangzhou Dahua recorded net profit attributable to the parent of 101 million yuan, up 330.75 percent. In addition, companies including Lianchuang Co., Huarui Precision, Jifeng Auto Parts, Zhongxing Fungus, Boliwei, Shengyi Electronics, and Satellite Chemical also saw net profit attributable to the parent rise by more than 100 percent year on year.